Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc .
Toggle Summary Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 th at 9:30 a.m. ET . A live audio webcast of the presentation will be available under the
Toggle Summary Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Kevin Horgan , M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b
Toggle Summary Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
Toggle Summary Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Dr. Horgan, an immunology and oncology drug development expert, is well positioned to drive Seres microbiome clinical programs forward CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced the appointment of Kevin Horgan , M.D., as Executive
Toggle Summary Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced it will present new data for SER-109, a microbiome candidate in Phase 3 development, at
Toggle Summary Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced the appointment of Meryl Zausner , a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the
Toggle Summary Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
- Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis - - Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end - - Recent Seres R&D event highlighted microbiome scientific leadership across several
Toggle Summary Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 25, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.m. ET to discuss second quarter 2018 financial results and provide a general business update.
Toggle Summary Seres Therapeutics to Present at Two Upcoming June Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: Jefferies 2018 Global Healthcare Conference : a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m.

Back to top